China Universal Asset Management Co. Ltd. Purchases 10,052 Shares of Kymera Therapeutics, Inc. $KYMR

China Universal Asset Management Co. Ltd. lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 77.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,079 shares of the company’s stock after acquiring an additional 10,052 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Kymera Therapeutics were worth $1,007,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in Kymera Therapeutics by 7.0% in the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock worth $143,183,000 after purchasing an additional 344,080 shares during the period. Invesco Ltd. lifted its position in Kymera Therapeutics by 36.9% during the 1st quarter. Invesco Ltd. now owns 42,075 shares of the company’s stock valued at $1,152,000 after purchasing an additional 11,343 shares during the period. Nuveen LLC bought a new position in shares of Kymera Therapeutics in the 1st quarter valued at about $3,920,000. Russell Investments Group Ltd. grew its position in shares of Kymera Therapeutics by 40.0% during the 1st quarter. Russell Investments Group Ltd. now owns 82,507 shares of the company’s stock worth $2,258,000 after buying an additional 23,584 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Kymera Therapeutics by 13.0% during the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company’s stock worth $164,134,000 after buying an additional 689,547 shares during the last quarter.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $89.76, for a total transaction of $448,800.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jared Gollob sold 49,307 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $88.67, for a total transaction of $4,372,051.69. Following the completion of the transaction, the insider owned 109,992 shares of the company’s stock, valued at $9,752,990.64. This trade represents a 30.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 597,805 shares of company stock worth $46,839,199 in the last quarter. Company insiders own 16.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on KYMR shares. Morgan Stanley raised their price objective on shares of Kymera Therapeutics from $73.00 to $127.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th. Mizuho increased their price target on Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a research note on Thursday. UBS Group raised Kymera Therapeutics to a “strong-buy” rating in a research note on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Wednesday, October 8th. Finally, Guggenheim initiated coverage on Kymera Therapeutics in a report on Monday, November 3rd. They set a “buy” rating and a $90.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $112.80.

Kymera Therapeutics Trading Up 2.1%

Shares of Kymera Therapeutics stock opened at $89.68 on Monday. The stock’s fifty day simple moving average is $64.77 and its 200 day simple moving average is $52.18. The company has a market capitalization of $6.45 billion, a PE ratio of -24.98 and a beta of 2.28. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.19). The business had revenue of $2.76 million during the quarter, compared to the consensus estimate of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. Analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.